琥珀酸美托洛尔缓释片联合稳心颗粒治疗冠心病心律失常疗效观察

摘要

Objective It is to explore the curative effect of metroprolol succinate sustained-release tablets and wenxin particle on coronary artery disease ( CAD ) with arrhythmia and to explore its safety. Methods Eighty-six patients with CAD and arrhythmia were randomly divided into 2 group: observation group treated with metroprolol succinate sustained-release tablets combined with wenxin particle and control group treated with metroprolol succinate sustained-release tablets alone. After four weeks' treatment, the therapeutic effect were compared and the difference in each index of dynamic electrocardiogram with 24 h between the two groups were analyzed, adverse reaction was observed at the same time. Results After 4 weeks' treatment, the times of ventricualr premature beats, atrial premature beats and junctional premature beats of observation group were less than that of control group. Every index of heart rate variability ( HRV )of both groups were improved, and SDNN in observation group was higher than that in control group. Conclusion The clinical curative effect of metroprolol succinate sustained-release tablets and wenxin particle on CAD with arrhythmia is obvious, which is worth to be widely used.%目的 探讨琥珀酸美托洛尔缓释片联合稳心颗粒治疗冠心病(CAD)心律失常的疗效和用药的安全性.方法 将86例冠心病心律失常患者随机分为2组:观察组45例采用琥珀酸美托洛尔缓释片和稳心颗粒治疗,对照组41例仅给予琥珀酸美托洛尔缓释片治疗.治疗4周后比较2组的疗效并分析2组治疗前后24h动态心电图各指标的差异,同时观察药物的不良反应.结果 治疗4周后,观察组室性早搏数、房性早搏数、交界性早搏数均少于对照组;2组心率变异各指标均有改善,且观察组的SDNN值高于对照组.结论 琥珀酸美托洛尔缓释片联合稳心颗粒治疗冠心病心律失常临床疗效确切,值得临床推广应用.